-
Development and implementation of a prescription opioid registry across diverse health systems.
Ray GT, et al. Development and implementation of a prescription opioid registry across diverse health systems. JAMIA Open 2022;5(2):ooac030.
-
Effects of buprenorphine dose and therapeutic engagement on illicit opiate use in opioid use disorder treatment trials.
Bergen AW, Baurley JM, Ervin CM, McMahan CS, Bible J, Stafford RS, Mudumbai SC, Saxon AJ. Effects of buprenorphine dose and therapeutic engagement on illicit opiate use in opioid use disorder treatment trials. International Journal of Environmental Research and Public Health 2022; 19(7): 4106.
-
Predictors of therapeutic alliance, treatment feedback, and clinical outcomes among African American women in treatment for co-occurring PTSD and SUD.
Bauer AG, Ruglass LM, Shevorykin A, Saraiya TC, Robinson G, Cadet K, Julien L, Chao T, Hien DA. Predictors of therapeutic alliance, treatment feedback, and clinical outcomes among African American women in treatment for co-occurring PTSD and SUD. Journal of Substance Abuse Treatment 2022;139:108766.
-
The Opioid Use Disorder Core Outcomes Set (OUD-COS) for treatment research: Findings from a Delphi consensus study.
Karnik J, Marsden J, McCluskey C, Boley RA, Bradley KA, Campbell CI, Curtis ME, Fiellin D, Ghitza U, Hefner K, Hser Y, McHugh RK, McPherson SM, Mooney LJ, Moran LM, Murphy SM, Schwartz RP, Shmueli-Blumberg D, Shulman M, Stephens KA, Watkins KE, Weiss RD, Wu L. The Opioid Use Disorder Core Outcomes Set (OUD-COS) for treatment research: Findings from a Delphi consensus study. Addiction 2022;117(9):2438-2447.
-
Chronic alcohol exposure among people living with HIV is associated with innate immune activation and alterations in monocyte phenotype and plasma cytokine profile.
Underwood ML, Park B, Uebelhoer LS, Gu G, Kunkel LE, Korthuis PT, Cook RR, Sekaly RP, Ribeiro SP, Lancioni CL. Chronic alcohol exposure among people living with HIV is associated with innate immune activation and alterations in monocyte phenotype and plasma cytokine profile. Frontiers in Immunology 2022;13:867937.
-
Revisiting the X:BOT naltrexone clinical trial using a comprehensive survival analysis.
Ajazai EM, Dasgupta N, Marshall SW, Monaco J, Howard AG, Preisser JS, Schwartz TA. Revisiting the X:BOT naltrexone clinical trial using a comprehensive survival analysis. Journal of Addiction Medicine 2022;16(4):440-446.
-
Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder.
Sherma BJ, Sofis MJ, Borodovsky JT, Gray KM, McRae-Clark AL, Budney AJ. Evaluating cannabis use risk reduction as an alternative clinical outcome for cannabis use disorder. Psychology of Addictive Behaviors 2022;36(5):505-514.
-
HIV clinic-based extended release naltrexone versus treatment as usual for people with HIV and opioid use disorder: A non-blinded, randomised non-inferiority trial.
Korthuis PT, Cook RR, Lum P, Waddell EN, Tookes H, Vergara-Rodriguez P, Kunkel LE, Lucas GM, Rodriguez A, Bielavitz S, Fanucchi L, Hoffman K, Bachrach K, Payne EH, Collins JA, Matthews A, Oden N, Jacobs P, Jelstrom E, Sorensen JL, McCarty D. HIV clinic-based extended release naltrexone versus treatment as usual for people with HIV and opioid use disorder: A non-blinded, randomised non-inferiority trial. Addiction 2022;117(7):1961-1971.
-
Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain.
Edwards KA, Vowles KE, McHugh RK, Venner KL, Witkiewitz K. Changes in pain during buprenorphine maintenance treatment among patients with opioid use disorder and chronic pain. Journal of Consulting and Clinical Psychology 2022;90(4):317-325.
-
Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the prodynorphin gene.
Nielsen DA, Walker R, Graham DP, Nielsen EM, Hamon SC, Hillhouse M, Shmueli-Blumberg D, Lawson WB, Shores-Wilson K, Settles-Reaves BD, Rotrosen J, Trivedi MH, Saxon AJ, Ling W, Kosten TR. Moderation of buprenorphine therapy for cocaine dependence efficacy by variation of the prodynorphin gene. European Journal of Clinical Pharmacology 2022;78:965-973.